- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07652190
Comparison of Day Hospitalization Versus Full-Time Hospitalization in the Treatment of Severe Adolescent Obesity (MAROSA)
11. juni 2026 opdateret af: Fondation Santé des Étudiants de France
Comparison of Day Hospitalization and Full-Time Hospitalization in the Treatment of Severe Adolescent Obesity (MAROSA)
This multicenter prospective quasi-experimental study aims to compare the effectiveness of day hospitalization versus full-time hospitalization for adolescents with severe obesity.
The primary outcome is the change in BMI z-score measured six months after the end of treatment.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study evaluates two healthcare delivery models for adolescents with severe obesity: day hospitalization and full-time hospitalization.
It examines clinical, biological, psychological, and social outcomes, as well as patient satisfaction and predictors of response.
The objective is to identify patient profiles that benefit most from each treatment modality to optimize care pathways
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
126
Fase
- Ikke anvendelig
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Adolescents aged 12-20 years
- Severe obesity (IOTF > 30)
- Admitted to participating centers
- Covered by health insurance
- Signed informed consent (participant or legal guardian)
Exclusion Criteria:
- Acute psychiatric disorder requiring hospitalization
- Secondary obesity due to endocrine disorders
- Age < 12 or > 20 years
- Inability to provide consent Emergency situation Refusal to participate
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: Day Hospitalization (DH)
Multidisciplinary day hospital program for adolescents with severe obesity, including medical follow-up, nutritional counseling, physical activity, and psychological support, provided during daytime without overnight stay.
|
Adolescents with severe obesity involved in a day hospital program following standard multidisciplinary care will receive treatment as usual, including medical monitoring, nutritional counseling, physical activity, and psychological support provided during daytime sessions without overnight stay.
|
|
Andet: Full-Time Hospitalization (FTH)
Multidisciplinary full-time hospitalization program for adolescents with severe obesity, including medical follow-up, nutritional counseling, physical activity, and psychological support, provided with continuous inpatient care.
|
subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks) Adapted Physical Activity program, including psychoeducation on both problematic physical activity and consequences in terms of physical activity good practice leads to a better outcome among persons suffering from anorexia nervosa.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
hange in BMI z-score
Tidsramme: From date of admission (baseline, T0) until the first occurrence of [event of interest], assessed up to 9 months after inclusion.
|
BMI z-score calculated based on weight, height, sex, and age
|
From date of admission (baseline, T0) until the first occurrence of [event of interest], assessed up to 9 months after inclusion.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain intensity assessed using Visual Analog Scale (VAS)
Tidsramme: Baseline and end of treatment (3 months)
|
Pain intensity will be measured using a 0-10 Visual Analog Scale, where 0 indicates no pain and 10 indicates worst imaginable pain.
|
Baseline and end of treatment (3 months)
|
|
Quality of life assessed using the SF-36 questionnaire
Tidsramme: Baseline and end of treatment (3 months)
|
Quality of life will be assessed using the Short Form-36 (SF-36), which includes 8 domains.
Scores range from 0 to 100, with higher scores indicating better quality of life.
|
Baseline and end of treatment (3 months)
|
|
Anxiety and depression assessed using the Hospital Anxiety and Depression Scale (HADS)
Tidsramme: Baseline and end of treatment (3 months)
|
The HADS questionnaire consists of 14 items, with two subscales (anxiety and depression), each ranging from 0 to 21.
Higher scores indicate greater symptom severity.
|
Baseline and end of treatment (3 months)
|
|
Fatigue assessed using the Fatigue Severity Scale (FSS)
Tidsramme: Baseline and end of treatment (3 months)
|
Fatigue will be measured using the Fatigue Severity Scale, consisting of 9 items rated on a 1 to 7 scale.
Higher scores indicate greater fatigue severity.
|
Baseline and end of treatment (3 months)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
5. oktober 2026
Primær færdiggørelse (Anslået)
10. oktober 2027
Studieafslutning (Anslået)
10. november 2027
Datoer for studieregistrering
Først indsendt
12. maj 2026
Først indsendt, der opfyldte QC-kriterier
11. juni 2026
Først opslået (Faktiske)
16. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
16. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
11. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2025-A00705-44
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Pædiatrisk fedme
-
Cairo UniversityRekrutteringSuprakondylær Humeral Fracture in PediatricEgypten
Kliniske forsøg med Day Hospital Multidisciplinary Care
-
Médipôle Lyon-VilleurbanneAktiv, ikke rekrutterende
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyAfsluttetAvanceret solid tumorForenede Stater, Australien, Spanien, Sydkorea, Japan